Urinary Biomarkers for Neurodegenerative Diseases

Overview

Journal Exp Neurobiol

Specialty Neurology

Date 2020 Nov 6

PMID 33154195

Citations 15

Authors

Wongi Seol

Hyejung Kim

Ilhong Son

Affiliations

Soon will be listed here.

Abstract

Global incidence of neurodegenerative diseases (NDDs) such as Alzheimer's disease (AD) and Parkinson's disease (PD) is rapidly increasing, but the diagnosis of these diseases at their early stage is challenging. Therefore, the availability of reproducible and reliable biomarkers to diagnose such diseases is more critical than ever. In addition, biomarkers could be used not only to diagnose diseases but also to monitor the development of disease therapeutics. Urine is an excellent biofluid that can be utilized as a source of biomarker to diagnose not only several renal diseases but also other diseases because of its abundance in invasive sampling. However, urine was conventionally regarded as inappropriate as a source of biomarker for neurodegenerative diseases because it is anatomically distant from the central nervous system (CNS), a major pathologic site of NDD, in comparison to other biofluids such as cerebrospinal fluid (CSF) and plasma. However, recent studies have suggested that urine could be utilized as a source of NDD biomarker if an appropriate marker is predetermined by metabolomic and proteomic approaches in urine and other samples. In this review, we summarize such studies related to NDD.

Citing Articles

Mitochondrial Dysfunction in Neurodegenerative Diseases.

Yang H Cells. 2025; 14(4).

PMID: 39996748 PMC: 11853439. DOI: 10.3390/cells14040276.

Diagnostic and prognostic performance of urine ubiquitin carboxy-terminal hydrolase L1 across multiple acute brain injury types - A longitudinal prospective cohort study.

Hellstrom S, Sajanti A, Jhaveri A, Srinath A, Bennett C, Cao Y Brain Spine. 2025; 5:104173.

PMID: 39834718 PMC: 11743582. DOI: 10.1016/j.bas.2024.104173.

Biological Function Analysis of MicroRNAs and Proteins in the Cerebrospinal Fluid of Patients with Parkinson's Disease.

Hwang J, Kim S, George N, Kwon M, Jang Y, Lee S Int J Mol Sci. 2025; 25(24.

PMID: 39769025 PMC: 11678473. DOI: 10.3390/ijms252413260.

Urine metabolomics phenotyping and urinary biomarker exploratory in mild cognitive impairment and Alzheimer's disease.

Wang Y, Sun Y, Wang Y, Jia S, Qiao Y, Zhou Z Front Aging Neurosci. 2024; 15:1273807.

PMID: 38187356 PMC: 10768723. DOI: 10.3389/fnagi.2023.1273807.

Editorial: Present and future of biological fluid biomarkers in dementia.

Frontinan-Rubio J, Rabanal-Ruiz Y, Peinado J, Deierborg T Front Aging Neurosci. 2023; 15:1331799.

PMID: 38076546 PMC: 10704162. DOI: 10.3389/fnagi.2023.1331799.

References

Hanke M, Kausch I, Dahmen G, Jocham D, Warnecke J . Detailed technical analysis of urine RNA-based tumor diagnostics reveals ETS2/urokinase plasminogen activator to be a novel marker for bladder cancer. Clin Chem. 2007; 53(12):2070-7. DOI: 10.1373/clinchem.2007.091363. View

Bolner A, Pilleri M, De Riva V, Nordera G . Plasma and urinary HPLC-ED determination of the ratio of 8-OHdG/2-dG in Parkinson's disease. Clin Lab. 2012; 57(11-12):859-66. View

Bishnoi M, Chopra K, Kulkarni S . Possible anti-oxidant and neuroprotective mechanisms of zolpidem in attenuating typical anti-psychotic-induced orofacial dyskinesia: a biochemical and neurochemical study. Prog Neuropsychopharmacol Biol Psychiatry. 2007; 31(5):1130-8. DOI: 10.1016/j.pnpbp.2007.04.007. View

Froula J, Castellana-Cruz M, Anabtawi N, Camino J, Chen S, Thrasher D . Defining α-synuclein species responsible for Parkinson's disease phenotypes in mice. J Biol Chem. 2019; 294(27):10392-10406. PMC: 6615698. DOI: 10.1074/jbc.RA119.007743. View

Wiedrick J, Phillips J, Lusardi T, McFarland T, Lind B, Sandau U . Validation of MicroRNA Biomarkers for Alzheimer's Disease in Human Cerebrospinal Fluid. J Alzheimers Dis. 2019; 67(3):875-891. PMC: 6687305. DOI: 10.3233/JAD-180539. View

Cui Y, Liu X, Wang M, Liu L, Sun X, Ma L . Lysophosphatidylcholine and amide as metabolites for detecting alzheimer disease using ultrahigh-performance liquid chromatography-quadrupole time-of-flight mass spectrometry-based metabonomics. J Neuropathol Exp Neurol. 2014; 73(10):954-63. DOI: 10.1097/NEN.0000000000000116. View

Ku B, Kim H, Kim Y, Ryu H . Comparison of Urinary Alzheimer-Associated Neural Thread Protein (AD7c-NTP) Levels Between Patients With Amnestic and Nonamnestic Mild Cognitive Impairment. Am J Alzheimers Dis Other Demen. 2019; 35:1533317519880369. PMC: 10623931. DOI: 10.1177/1533317519880369. View

Wang Z, Hill S, Luther J, Hachey D, Schey K . Proteomic analysis of urine exosomes by multidimensional protein identification technology (MudPIT). Proteomics. 2011; 12(2):329-38. PMC: 3517144. DOI: 10.1002/pmic.201100477. View

Arshad A, Sulaiman S, Saperi A, Jamal R, Mohamed Ibrahim N, Abdul Murad N . MicroRNAs and Target Genes As Biomarkers for the Diagnosis of Early Onset of Parkinson Disease. Front Mol Neurosci. 2017; 10:352. PMC: 5671573. DOI: 10.3389/fnmol.2017.00352. View

10.

Butcher J . Urine tests for Alzheimer's disease--are they fool's gold?. Lancet Neurol. 2007; 6(2):106-7. DOI: 10.1016/S1474-4422(07)70015-7. View

11.

Izadpanah M, Seddigh A, Barough S, Shahzadeh Fazeli S, Ai J . Potential of Extracellular Vesicles in Neurodegenerative Diseases: Diagnostic and Therapeutic Indications. J Mol Neurosci. 2018; 66(2):172-179. DOI: 10.1007/s12031-018-1135-x. View

12.

Yao F, Hong X, Li S, Zhang Y, Zhao Q, Du W . Urine-Based Biomarkers for Alzheimer's Disease Identified Through Coupling Computational and Experimental Methods. J Alzheimers Dis. 2018; 65(2):421-431. DOI: 10.3233/JAD-180261. View

13.

Burgos K, Javaherian A, Bomprezzi R, Ghaffari L, Rhodes S, Courtright A . Identification of extracellular miRNA in human cerebrospinal fluid by next-generation sequencing. RNA. 2013; 19(5):712-22. PMC: 3677285. DOI: 10.1261/rna.036863.112. View

14.

Danborg P, Simonsen A, Waldemar G, Heegaard N . The potential of microRNAs as biofluid markers of neurodegenerative diseases--a systematic review. Biomarkers. 2014; 19(4):259-68. DOI: 10.3109/1354750X.2014.904001. View

15.

Weber J, Baxter D, Zhang S, Huang D, Huang K, Lee M . The microRNA spectrum in 12 body fluids. Clin Chem. 2010; 56(11):1733-41. PMC: 4846276. DOI: 10.1373/clinchem.2010.147405. View

16.

Nam D, Lee J, Lee M, Kim J, Seol W, Son I . Detection and Assessment of α-Synuclein Oligomers in the Urine of Parkinson's Disease Patients. J Parkinsons Dis. 2020; 10(3):981-991. DOI: 10.3233/JPD-201983. View

17.

Pena-Bautista C, Tirle T, Lopez-Nogueroles M, Vento M, Baquero M, Chafer-Pericas C . Oxidative Damage of DNA as Early Marker of Alzheimer's Disease. Int J Mol Sci. 2019; 20(24). PMC: 6940966. DOI: 10.3390/ijms20246136. View

18.

Wang S, Liu Z, Ye T, Mabrouk O, Maltbie T, Aasly J . Elevated LRRK2 autophosphorylation in brain-derived and peripheral exosomes in LRRK2 mutation carriers. Acta Neuropathol Commun. 2017; 5(1):86. PMC: 5700679. DOI: 10.1186/s40478-017-0492-y. View

19.

Nelson P, Wang W, Rajeev B . MicroRNAs (miRNAs) in neurodegenerative diseases. Brain Pathol. 2008; 18(1):130-8. PMC: 2859437. DOI: 10.1111/j.1750-3639.2007.00120.x. View

20.

Tan L, Yu J, Tan L . The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations. J Neurol Sci. 2012; 323(1-2):1-8. DOI: 10.1016/j.jns.2012.08.005. View